Nurse practitioners overrepresented among clinicians with the highest and lowest rates of inappropriate prescribing
MONDAY, Oct. 23, 2023 (HealthDay News) — Nurse practitioners (NPs) are no more likely to prescribe inappropriately than primary care physicians, according to a study published online Oct. 24 in the Annals of Internal Medicine.
Johnny Huynh, from the University of California in Los Angeles, and colleagues compared rates of inappropriate prescribing among 23,669 NPs and 50,060 primary care physicians who wrote prescriptions for 100 or more patients per year. Patients included Medicare Part D beneficiaries aged 65 years or older.
The researchers found that the mean rates of inappropriate prescribing were almost identical for NPs and primary care physicians (crude rates, 1.63 versus 1.69 per 100 prescriptions; adjusted rates, 1.66 and 1.68, respectively; adjusted odds ratio, 0.99; 95 percent confidence interval, 0.97 to 1.01). Among clinicians with the highest and lowest rates of inappropriate prescribing, NPs were overrepresented. Discrepancies in inappropriate prescribing rates across states tended to be larger than discrepancies between practitioners within states .
“The authors” findings add to a long list of empirical work showing that NPs provide equal or better quality of care when compared with their physician colleagues in primary care,” Michelle S. Keller, Ph.D., and Catherine A. Sarkisian, M.D., both from the University of California in Los Angeles, write in an accompanying editorial.
Abstract/Full Text (subscription or payment may be required)
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria
Polypharmacy of Prescription Medications Increased for U.S. Older Adults
Low Hydroxychloroquine Intake, Blood Levels Linked to ASCVD Risk in Lupus
Blinatumomab Improves Event-Free Survival in Children With High-Risk B-Cell ALL
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors
Anifrolumab Tied to Lower Hospitalization, Infection Risk in Lupus
Therapies Compared for Newly Diagnosed Multiple Sclerosis